| Project/Area Number |
15K15375
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Collagenous pathology/Allergology
|
|---|
| Research Institution | Saitama Medical University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
TSUCHIDA Tetuya 埼玉医科大学, 医学部, 教授 (70126126)
NAKAMURA Kouichiro 埼玉医科大学, 医学部, 教授 (60175502)
KAWANO Masaaki 埼玉医科大学, 医学部, 准教授 (30447528)
TAKAGI Rie 埼玉医科大学, 医学部, 助手 (00569080)
|
|---|
| Project Period (FY) |
2015-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | メラノーマ / ロドデノール / 白斑症 / 自己免疫 / T細胞 / チロシナーゼ / HLA / 隠ぺい自己抗原 / がん免疫 |
|---|
| Outline of Final Research Achievements |
Rhododendrol, a phenolic compound contained in lightening/whitening cosmetics, can bind and inhibit tyrosinase, and was reported to induce leukoderma in Japan. Only 2% of the cosmetics users are affected, and tacrolimus is effective in the treatment. To test the hypothesis that the disease is an autoimmune disorder, short-term T-cell lines were established using PBMCs from 8 patients with human melanoma-associated and tyrosinase-derived synthetic peptides. Seven out of 8 patients were positive for HLA-DR4. Both class I- and class II-restricted and tyrosinase peptide-specific T-cell responses were observed. Immunization of mice with rhododendrol-treated and irradiated B16 melanoma cells successfully delayed the growth of melanoma cells in vivo. These observations collectively indicate that rhododendrol-induced leukoderma is an autoimmune disorder, with rhododendrol as an environmental factor and HLA-DR4 as a genetic factor. Rhododendrol might be effective in treating melanomas.
|
